This post is sponsored by the MidAmerica Healthcare Venture Forum.
At The MidAmerica Healthcare Venture Forum hosted at Chicago’s Fairmont Hotel on March 10 and 11, Healthbox’s Maria Siambekos will host a session about the growing role of healthcare accelerators. Do investors invest in them?
“Accelerators have become as common as Band-Aids on the healthcare scene,” said Lisa Suennen of Venture Valkyrie Consulting, who will be moderating a panel on the topic at the MidAmerica Healthcare Venture Forum (MHVF). “What started as a movement is now having to progress to a business model. It is interesting to see how the field is segmenting and shifting to better define its value proposition to entrepreneurs, investors and the marketplace.”
Suennen delves deeper into this topic with Jeff Makowka, director, thought leadership of AARP, on the MHVF panel, “Litmus test on Healthcare Accelerators.”
With nearly 90 dedicated health accelerators in the United States according to a recent report from the California Healthcare Foundation, there is a lot of national and industry discussion on identifying an accelerator that is the right “fit.” It’s all about the match between mentor, money and medicine.
According to Crain’s NY, there’s been a 228 percent funding growth in their health tech innovations in the last year alone, making accelerators another growth strategy early stage executives have to explore and seriously consider.
Join us in Chicago, share your experiences and insights and learn from industry leaders. Register now to reserve your spot.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
